Company: ANIX
Filing Date: 2025-09-10
Form Type: S-3
Source: 0001493152-25-013010
Chunk: 4

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: S-3
Chunk 4
---
                                          |
| ● | subscription                                                                                                                         
 rights to purchase any of the foregoing securities;                                                                                  |
| ● | depositary                                                                                                                           
 shares;                                                                                                                              |
| ● | secured                                                                                                                              
 or unsecured debt securities consisting of notes, debentures or other evidences of indebtedness which may be senior debt securities, 
 senior subordinated debt securities or subordinated debt securities, each of which may be convertible into equity securities; or     |
| ● | units                                                                                                                                
 comprised of, or other combinations of, the foregoing securities.                                                                    |

We may offer and sell these securities separately or together, in one or more series or classes and in amounts, at prices and on terms described in one or more offerings. We may offer securities through underwriting syndicates managed or co-managed by one or more underwriters or dealers, through agents or directly to purchasers. The prospectus supplement for each offering of securities will describe in detail the plan of distribution for that offering. For general information about the distribution of securities offered, please see “Plan of Distribution” in this prospectus.

Each time our securities are offered, we will provide a prospectus supplement containing more specific information about the particular offering and attach it to this prospectus. The prospectus supplements may also add, update or change information contained in this prospectus.

This prospectus may not be used to offer or sell securities without a prospectus supplement which includes a description of the method and terms of this offering.

Our common stock is quoted on the Nasdaq Capital Market under the symbol “ANIX.” The last reported sale price of our common stock on the NASDAQ Capital Market on September 9, 2025 was $2.98 per share. The aggregate market value of our outstanding common stock held by non-affiliates was $107,219,609 based on 32,916,915 shares of outstanding common stock, of which 31,168,491 shares are held by non-affiliates, and a per share price of $3.44 which was the closing sale price of our common stock as quoted on the NASDAQ Capital Market on July 18, 2025.

If we decide to seek a listing of any preferred stock, purchase contracts, warrants, subscriptions rights, depositary shares, debt securities or units offered by this prospectus, the related prospectus supplement will disclose the exchange or market on which the securities will be listed, if any, or where we have made an application for listing, if any.

Investing in our securities involves certain risks